Director/PDMR Shareholding

RNS Number : 2703V

Genedrive PLC

05 April 2019

 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that it has granted share options ("Options") to members of its senior management team to acquire a total of 1,330,000 ordinary shares of 1.5p each in the capital of the Company under the Company's Share Option Scheme.

The Options have been granted with an exercise price equal to the close price on the day before grant and vest after a period of three years. The Options are exercisable over the period of 10 years from the date of grant.

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1.	Details of the person discharging managerial responsibilities / person closely associated
a.	Name	David Budd CEO Matthew Fowler CFO Gino Miele R&D Director Gordon Powell Commercial Director Colleen Pythian Director of Quality & Regulation Warren Berry Operations Director
2.	Reason for the notification
a.	Position/status	1.
a.	Initial notification /Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	genedrive plc
b.	LEI	213800ZYODIRZ87Y4K14
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	Options over ordinary shares of 1.5 pence each
b.	Nature of the transaction	Grant of options pursuant to and in accordance with the terms of the Company's Share Option Scheme dated 29 November 2017.
c.	Price(s) and volume(s)	Option price(s) Volume(s) David Budd 23.5p 540,000 Matthew Fowler 23.5p 340,000 Gino Miele 23.5p 150,000 Gordon Powell 23.5p 150,000 Colleen Pythian 23.5p 75,000 Warren Berry 23.5p 75,000
d.	Aggregated information ·      Aggregated volume ·      Price	N/A
e.	Date of the transaction	2019-April-04; UTC time
f.	Place of the transaction	Outside trading venue - shares to be admitted to AIM market of London Stock Exchange plc on exercise of options

For further details please contact:

genedrive plc	[phone]
David Budd: CEO
Matthew Fowler: CFO
Peel Hunt LLP	[phone]
James Steel / Oliver Jackson
Stanford Capital Partners Limited	[phone]
Patrick Claridge / John Howes
Walbrook PR Ltd (Media Relations & Investor Relations)	[phone] or [e-mail]
Paul McManus / Anna Dunphy

 

END

 

 

DSHEAXLSEAPNEEF